TuHURA Biosciences (HURA) and Kineta (KANT) Receive Stockholders Approval of Proposed Merger and All Related Proposals Jun 23, 2025 05:02PM
TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals Jun 23, 2025 05:00PM
Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024) Nov 8, 2024 09:00AM
Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors Oct 8, 2024 09:00AM
Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 Oct 4, 2024 09:05AM


Oct 2, 2024 04:05PM Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1
Sep 20, 2024 06:16AM Kineta (KA) Delisting to OTC
Sep 19, 2024 06:23PM Kineta, Inc Transitioning from Nasdaq to OTC Markets